A major backer of the Alzheimer’s Association is pushing to change the way we categorize Alzheimer’s disease based on a brain study published in Neurology. The research places Alzheimer’s firmly in third place as a leading cause of death in America, instead of its current position of sixth.

The global breast imaging market is expected to rise at a compound annual growth rate of 15.37 percent until 2017 reaching a total worth of $5 billion, announced research firm RnRMarketResearch.com today.

F-18 florbetaben, also known as Neuraceq, received U.S. Food and Drug Administration (FDA) approval today as a diagnostic amyloid agent to help rule out Alzheimer’s disease.

Singapore-based Zecotek Photonics has announced that a new micro-channel avalanche photodiode solid-state photo detector (MAPD) to be used in advanced PET technology has received a notice of allowance from the U.S. Patent Office.

Lisa Berrios-Moore was honored by the National Association of Professional Women this week with the prestigious award and recognition as VIP Woman of the Year for her leadership in healthcare. 

The worldwide nuclear medicine industry is expected to grow an annual percentage rate of 11 percent, mostly due to a steady 30 percent climb in therapeutic radiopharmaneticals every year between 2013 and 2030, according to a March 2014 market report by European research firm MEDraysintell.

Aethlon and subsidiary Exosome Sciences, both based in San Diego, Calif., announced earlier this month that the companies have isolated blood-borne biomarkers implicated in multiple neurodegenerative diseases.

A novel theranostic agent has the ability to target melanoma and provide radionuclide therapy in preliminary investigation, according to a study published March 13 in the Journal of Nuclear Medicine.